SECURITIES NOTICE: Rosen Law Firm Reminds Spectrum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action Filed by Firm- SPPI

NEW YORK, Sept. 30, 2016

To join the Spectrum class action, go to the website at http://www.rosenlegal.com/cases-955.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.  YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA previously questioned whether the data from the 611 and 612 Studies were clinically meaningful; (2) the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) as a result, defendants' public statements about Spectrum's business, operations and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Attorney Advertising.  Prior results do not guarantee a similar outcome.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 21, 2016. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-955.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.